Press Releases

Press Releases

Nov 16, 2023

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Nov 06, 2023

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 06, 2023

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Oct 31, 2023

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

Oct 31, 2023

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

Oct 16, 2023

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Sep 27, 2023

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 07, 2023

CRISPR Therapeutics Announces Leadership Transition

Aug 30, 2023

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

Aug 07, 2023

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Jun 13, 2023

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Jun 09, 2023

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Jun 08, 2023

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

May 08, 2023

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 02, 2023

CRISPR Therapeutics to Participate Upcoming Investor Conferences

Apr 13, 2023

CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

Apr 03, 2023

CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Mar 29, 2023

CRISPR Therapeutics Announces Departure of Board Member

Mar 27, 2023

CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

Mar 14, 2023

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

Mar 13, 2023

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Feb 27, 2023

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 21, 2023

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 08, 2023

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Jan 11, 2023

CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference